We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots (WBA) Tops Q4 Earnings, Misses on Revenues
Read MoreHide Full Article
Are you a frequent visitor to retail drugstores? Then you must have come across at least one of the 13,100 drugstores operated by Walgreens Boots Alliance, Inc. (WBA - Free Report) . This Illinois-based company is the first global pharmacy-led, health and wellbeing enterprise.
Currently, Walgreens Boots has a Zacks Rank #3 (Hold) but that could change following its mixed fourth quarter fiscal 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 99 cents per share over the last 60 days. Walgreens Boots’ adjusted earnings per share of $1.07 beat this estimate by 8.1%.
Revenues: Walgreens posted revenues of $28.6 billion and missed the Zacks Consensus Estimate for revenues of $29.9 billion.
Key Stats: Revenue from the Retail Pharmacy USA division increased 4.0% to $20.7 billion, while revenues from the Pharmaceutical Wholesale division fell 6.2% to $5.4 billion. However, revenues from the Retail Pharmacy International division dropped 10.9% to $3.0 billion. Moreover, Walgreens Boots filled 229.5 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, reflecting an increase of 3.7 % over third quarter of fiscal 2015.
Major Factors: Per management, Walgreens Boots delivered solid results on a year over year basis in the fiscal fourth quarter, while continuing to make progress in several key areas, including development in the company’s long-term strategic relationships and pursuing partnership opportunities. With respect to the impending Rite Aid takeover, the company in a separate press release announced that it has extended the closing date of the merger agreement from 27 October 2016 to 27 January 2017. The company has also provided adjusted earnings per share guidance for fiscal 2017 in the range of $4.85 to $5.20.
Stock Price: Following the earnings release, share prices dropped 0.23% during the pre-market trading session.
Check back later for our full write up on this Walgreens Boots earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Walgreens Boots (WBA) Tops Q4 Earnings, Misses on Revenues
Are you a frequent visitor to retail drugstores? Then you must have come across at least one of the 13,100 drugstores operated by Walgreens Boots Alliance, Inc. (WBA - Free Report) . This Illinois-based company is the first global pharmacy-led, health and wellbeing enterprise.
Currently, Walgreens Boots has a Zacks Rank #3 (Hold) but that could change following its mixed fourth quarter fiscal 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 99 cents per share over the last 60 days. Walgreens Boots’ adjusted earnings per share of $1.07 beat this estimate by 8.1%.
WALGREENS BAI Price and EPS Surprise
WALGREENS BAI Price and EPS Surprise | WALGREENS BAI Quote
Revenues: Walgreens posted revenues of $28.6 billion and missed the Zacks Consensus Estimate for revenues of $29.9 billion.
Key Stats: Revenue from the Retail Pharmacy USA division increased 4.0% to $20.7 billion, while revenues from the Pharmaceutical Wholesale division fell 6.2% to $5.4 billion. However, revenues from the Retail Pharmacy International division dropped 10.9% to $3.0 billion. Moreover, Walgreens Boots filled 229.5 million prescriptions (including immunizations) on a 30-day adjusted basis in the quarter, reflecting an increase of 3.7 % over third quarter of fiscal 2015.
Major Factors: Per management, Walgreens Boots delivered solid results on a year over year basis in the fiscal fourth quarter, while continuing to make progress in several key areas, including development in the company’s long-term strategic relationships and pursuing partnership opportunities. With respect to the impending Rite Aid takeover, the company in a separate press release announced that it has extended the closing date of the merger agreement from 27 October 2016 to 27 January 2017. The company has also provided adjusted earnings per share guidance for fiscal 2017 in the range of $4.85 to $5.20.
Stock Price: Following the earnings release, share prices dropped 0.23% during the pre-market trading session.
Check back later for our full write up on this Walgreens Boots earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>